CLN5 purified MaxPab mouse polyclonal antibody (B01P)
* The price is valid only in USA. Please select country.
-
More Files
- More Functions
-
Specification
Product Description
Mouse polyclonal antibody raised against a full-length human CLN5 protein.
Immunogen
CLN5 (AAI53155.1, 1 a.a. ~ 407 a.a) full-length human protein.
Sequence
MRRNLRLGPSSGADAQGQGAPRPGLAAPRMLLPPASQASRGSGSTGCSLMAQEVDTAQGAEMRRGAGAARGRASWCWALALLWLAVVPGWSRVSGIPSRRHWPVPYKRFDFRPKPDPYCQAKYTFCPTGSPIPVMEGDDDIEVFRLQAPVWEFKYGDLLGHLKIMHDAIGFRSTLTGKNYTMEWYELFQLGNCTFPHLRPEMDAPFWCNQGAACFFEGIDDVHWKENGTLVQVATISGNMFNQMAKWVKQDNETGIYYETWNVKASPEKGAETWFDSYDCSKFVLRTFNKLAEFGAEFKNIETNYTRIFLYSGEPTYLGNETSVFGPTGNKTLGLAIKRFYYPFKPHLPTKEFLLSLLQIFDAVIVHKQFYLFYNFEYWFLPMKFPFIKITYEEIPLPIRNKTLSGL
Host
Mouse
Reactivity
Human
Interspecies Antigen Sequence
Mouse (79)
Quality Control Testing
Antibody reactive against mammalian transfected lysate.
Storage Buffer
In 1x PBS, pH 7.4
Storage Instruction
Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
-
Applications
Western Blot (Transfected lysate)
Western Blot analysis of CLN5 expression in transfected 293T cell line (H00001203-T01) by CLN5 MaxPab polyclonal antibody.
Lane 1: CLN5 transfected lysate(44.77 KDa).
Lane 2: Non-transfected lysate.
-
Gene Info — CLN5
Entrez GeneID
1203GeneBank Accession#
BC153154.1Protein Accession#
AAI53155.1Gene Name
CLN5
Gene Alias
FLJ90628, NCL
Gene Description
ceroid-lipofuscinosis, neuronal 5
Gene Ontology
HyperlinkGene Summary
This gene is one of eight which have been associated with neuronal ceroid lipofuscinoses (NCL). Also referred to as Batten disease, NCL comprises a class of autosomal recessive, neurodegenerative disorders affecting children. The genes responsible likely encode proteins involved in the degradation of post-translationally modified proteins in lysosomes. The primary defect in NCL disorders is thought to be associated with lysosomal storage function
Other Designations
OTTHUMP00000018521
-
Interactome
-
Pathway
-
Disease
-
Publication Reference
-
CLN5 in Heterozygosis May Protect Against the Development of Tumors in a VHL Patient.
Isabel de Rojas-P, Virginia Albiñana, Lucía Recio-Poveda, Amanda Rodriguez-Rufián, Ángel M Cuesta, Luisa-María Botella.
Orphanet Journal of Rare Diseases 2020 Jun; 15(1):132.
Application:WB-Ce, Human, HB cells.
-
CLN5 in Heterozygosis May Protect Against the Development of Tumors in a VHL Patient.
- +1-909-264-1399
+1-909-992-0619
Toll Free : +1-877-853-6098 - +1-909-992-3401
- sales@abnova.com